Teleflex Incorporated (NYSE:TFX) today announced that the company has received reimbursement approval from the Central Social Insurance Medical Council of Japan (Chuikyo) of its UroLift System for patients who require

Teleflex Incorporated (NYSE:TFX) today announced that the company has received reimbursement approval from the Central Social Insurance Medical Council of Japan (Chuikyo) of its UroLift System for patients who require treatment for benign prostatic hyperplasia (BPH).
 

The UroLift System treatment is a minimally invasive approach to treating BPH, commonly known as an enlarged prostate, a condition that causes bothersome urinary symptoms in men. Performed as a same-day outpatient procedure,1 the UroLift System can help improve quality of life,2 and offers lasting relief from symptoms with minimal downtime for patients.1,3

Liam Kelly, Chairman, President and Chief Executive Officer said, "I am proud of how the team has achieved reimbursement approval for the UroLift System in Japan. We have strategically directed investment into developing our UroLift commercial and clinical capabilities in Japan and will be in a position to perform our first training cases in the first quarter of 2022. We are excited to bring this clinically beneficial treatment to the more than two million men suffering from BPH in Japan.4"

"The UroLift System is a major advancement in the treatment of BPH and can positively impact patients' quality of life. We are very excited to have this technology available soon in Japan and look forward to its use in treating our patients," said Satoru Takahashi, Professor and Chairman, Department of Urology, Nihon University School of Medicine.**

The newly approved reimbursement for the UroLift System in Japan goes into effect April 1, 2022. Teleflex currently plans to enroll a PMDA-mandated, post-market clinical study to expand its already robust clinical data on the efficacy of the UroLift System and support widespread adoption of the UroLift System in Japan.